These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 18601658)

  • 1. Outcome measures in immune-mediated neuropathies: the need to standardize their use and to understand the clinimetric essentials.
    van Nes SI; Faber CG; Merkies IS
    J Peripher Nerv Syst; 2008 Jun; 13(2):136-47. PubMed ID: 18601658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome measures in peripheral neuropathies: requirements through statements.
    Merkies IS; Lauria G; Faber CG
    Curr Opin Neurol; 2012 Oct; 25(5):556-63. PubMed ID: 22941264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to assess new drugs for neuropathies: advances in trial design and methodology.
    van Doorn PA; Merkies IS
    Curr Opin Neurol; 2008 Oct; 21(5):519-26. PubMed ID: 18769244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poor reporting of quality of life outcomes in dermatology randomized controlled clinical trials.
    Le Cleach L; Chassany O; Levy A; Wolkenstein P; Chosidow O
    Dermatology; 2008; 216(1):46-55. PubMed ID: 18032899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dysimmune neuropathies: current diagnosis and therapy].
    Léger JM; Larue S; Dashi F
    Rev Prat; 2008 Nov; 58(17):1887-9, 1892-4. PubMed ID: 19157204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatigue in immune-mediated neuropathies.
    Merkies IS; Faber CG
    Neuromuscul Disord; 2012 Dec; 22 Suppl 3():S203-7. PubMed ID: 23182640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Appraisal of primary outcome measures used in trials of patient decision support.
    Kryworuchko J; Stacey D; Bennett C; Graham ID
    Patient Educ Couns; 2008 Dec; 73(3):497-503. PubMed ID: 18701235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-based treatment of chronic immune-mediated neuropathies.
    Magy L; Vallat JM
    Expert Opin Pharmacother; 2009 Aug; 10(11):1741-54. PubMed ID: 19601698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life in inflammatory neuropathies: the IN-QoL.
    Draak THP; Faber CG; Merkies ISJ;
    J Neurol Neurosurg Psychiatry; 2018 Mar; 89(3):256-262. PubMed ID: 28986470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating patient-centered outcomes in the randomized controlled trial and beyond: informing the future with lessons from the past.
    Booth CM
    Clin Cancer Res; 2010 Dec; 16(24):5963-71. PubMed ID: 21169249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reporting on reliability and validity of outcome measures in medical rehabilitation research.
    Dijkers MP; Kropp GC; Esper RM; Yavuzer G; Cullen N; Bakdalieh Y
    Disabil Rehabil; 2002 Nov; 24(16):819-27. PubMed ID: 12450458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing the validity and utility of randomized clinical trials in addictions treatment research: II. Participant samples and assessment.
    Del Boca FK; Darkes J
    Addiction; 2007 Aug; 102(8):1194-203. PubMed ID: 17511752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Electrophysiological diagnosis of inflammatory neuropathies].
    Petiot P
    Rev Neurol (Paris); 2007 Sep; 163 Spec No 1():3S36-44. PubMed ID: 18087228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating nerves: a call to arms.
    Hughes RA
    J Peripher Nerv Syst; 2008 Jun; 13(2):105-11. PubMed ID: 18601655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inadequate planning and reporting of adjudication committees in clinical trials: recommendation proposal.
    Dechartres A; Boutron I; Roy C; Ravaud P
    J Clin Epidemiol; 2009 Jul; 62(7):695-702. PubMed ID: 19135860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the reporting and scientific quality of meta-analyses of randomized controlled trials of treatments for anxiety disorders.
    Bereza BG; Machado M; Einarson TR
    Ann Pharmacother; 2008 Oct; 42(10):1402-9. PubMed ID: 18728102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of intravenous immunoglobulin in multifocal motor neuropathy.
    Leger JM; Vargas S; Lievens I
    Ann N Y Acad Sci; 2007 Sep; 1110():248-55. PubMed ID: 17911439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Roaming through methodology. XII. Pragmatic and pathophysiologic trials: a question of goal formulation].
    Algra A; van der Graaf Y
    Ned Tijdschr Geneeskd; 1999 Mar; 143(10):514-7. PubMed ID: 10321260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.